ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
“There was really no option. This was their method of containing a person,” Guenter said. Before the drugs, Guenter found his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback